This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
LTZ Therapeutics, Inc.
LTZ Therapeutics, Inc.
Eli Lilly and Company
Masonic Cancer Center, University of Minnesota
Verismo Therapeutics
H. Lee Moffitt Cancer Center and Research Institute
University of Arizona
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Insel Gruppe AG, University Hospital Bern
Masonic Cancer Center, University of Minnesota
City of Hope Medical Center
Masonic Cancer Center, University of Minnesota
Cyteir Therapeutics, Inc.
Nkarta, Inc.
Atara Biotherapeutics
Scripps Health
Roswell Park Cancer Institute
Roswell Park Cancer Institute
Novartis
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Roswell Park Cancer Institute
Case Comprehensive Cancer Center
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Masonic Cancer Center, University of Minnesota
Roswell Park Cancer Institute
Roswell Park Cancer Institute
Fred Hutchinson Cancer Center
University of Maryland, Baltimore
University of Maryland, Baltimore
University of Maryland, Baltimore
Roswell Park Cancer Institute
University of Chicago
Case Comprehensive Cancer Center
M.D. Anderson Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Vanderbilt-Ingram Cancer Center
Fred Hutchinson Cancer Center
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
OHSU Knight Cancer Institute
OHSU Knight Cancer Institute
Fred Hutchinson Cancer Center